Prevention of the recurrence of HCC in patients with complete cure of HBV or HCV-positive HCC
Conditions
Interventions
investigational material(s)
Generic name etc : K-333
INN of investigational material : -
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material :
Sponsors
Kowa Company, Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients with the primary occurrence or the first recurrence of HBV- or HCV-related HCC (2)Patients showing that a complete cure was confirmed by either local ablation or surgical resection (3)Patients of the age of 20 years or older at the time of informed consent etc.
Exclusion criteria
Exclusion criteria: Patients with the HCC related to hepatitis virus other than HBV and HCV etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy confirmatory Recurrence-free survival Time to recurrence of HCC or death, regardless of cause | — |
Secondary
| Measure | Time frame |
|---|---|
| efficacy (1)Disease-free survival (2)Time to recurrence (1)Time to recurrence of HCC, death, regardless of cause, or occurrence of secondary cancer (2)Time to recurrence of HCC | — |
Countries
Asia except Japan
Outcome results
None listed